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The purpose of this study was to detect the presence of perchloric-acid-soluble protein 
(PSP) in blast cells of acute leukemic patients and to conduct in-vitro study on the 
possibility of blast cells be proliferated into matured cells when treated with PSP. Samples 
from acute myeloblastic leukemic (AML) patients and monocytes from healthy donor were 
used as a test subject. The small amount of perchloric-acid-soluble 14.5 kDa protein (PSP) 
was isolated from monocytes of healthy donor by a combination of trichloroacetic acid 
extraction, preparative electrophoresis and CM-Sephadex chromatography. However, this 
protein was not found in blast cells of AML patients. The 14.5 kDa protein showed a strong 
cross-reactivity when tested with PSP antibody suggesting a close similarity to p14.5 PSP 
found in mononuclear phagocytes of human. However in our in-vitro study on the 
proliferation of blast cells of AML samples after treated with PSP showed some reaction, 
but no significant results. Thus, we believed that the amount of PSP used in this study was 
too small which was not enough to play a significant role in cell development and maturity. 
Keywords: Acute leukemia; Perchloric-acid-soluble protein; blast cells; monocytes 
2 
4) Sila sediakan Laporan teknikallengkap yang menerangkan keseluruhan projek ini. 
[Sila gunakan kertas berasingan] 
Kindly prepare a comprehensive technical report explaining the project 
(Prepare report separately as attachment) 
Senaraikan Kata Kunci yang boleh menggambarkan penyelidikan anda : 
List a glosssary that explains or reflects your research: 
Bahasa Malaysia 
Leukemia akut 
Asid-Perklorik larut protin 
Sel blast 
Monosit 
Bahasa lnggeris 
Acute leukemia 
Perchloric-acid soluble protein 
Blast cellos 
Monocytes 
5) Output Dan Faedah Projek 
Output and Benefits of Project 
(a)* Penerbitan (termasuk laporan/kertas seminar) 
Publications (including reports/seminar papers) 
(b) 
(Sila nyatakan jenis, tajuk, pengarang, tahun terbitan dan di mana telah diterbitldibentangkan). 
(Kindly state each type, title, author/editor, publication year and joumaVs containing publication) 
Tiada 
······························································································································ 
······························································································································ 
Faedah-Faedah Lain Seperti Perkembangan Produk, Prospek Komersialisasi 
Dan Pendaftaran Paten atau impak kepada dasar dan masyakarat. 
Other benefits such as product development, product commercialisation/patent 
registration or impact on source and society 
······························································································································ 
Tiada 
······························································································································· 
······························································································································ 
······························································································································ 
······························································································································ 
······························································································································ 
······························································································································ 
* Sila berikan salinan 
* Kindly provide copies 
3 
(c) Latihan Gunatenaga Manusia 
Training in Human Resources 
i) Pelajar Siswazah : Tiada 
Postgraduate students: 
(perincikan nama, ijazah dan status) 
(Provide names, degrees and status) 
···························································································· 
····························································································· 
···························································································· 
ii) Pelajar Prasiswazah : Tiada 
Undergraduate students: 
(Nyatakan bilangan) 
(Provide number) 
iii) Lain-Lain : Tiada 
Others: 
···························································································· 
····························································································· 
···························································································· 
6. Peralatan Yang Telah Dibeli : 
Equipment that has been purchased: 
············································································································································· 
Tiada 
················································································································································ 
················································································································································ 
················································································································································ 
················································································································································ 
················································································································································ 
················································································································································ 
················································································································································ 
················································································································································ 
················································································································································ 
················································································································································ 
················································································································································ 
4 
UNTUK KEGUNAAN JAWATANKUASA PENYELIDIKAN UNIVERSITI 
/ 
............................. ~ ................................................................................................ . 
................................ .lt~ ....... 9..Mf~~-~---~-~w. ....... IL'?!.~· ........... . 
................................... 4.~·-···-f/Mf:. ........ ~.: ................................................. . 
·······································~·························································································· ·········································~~~~ ..... {:.~~---···~······~rfo-·~--~ 
........................................... 1"""~-~v. ............................................................. . 
. . 
···································································································································· 
···································································································································· 
···································································································································· 
···································································································································· 
............................. ~ .................................................................................................... . 
' 
PROFESSO . L A_BA 
Chairman of Research & Ethics Committee 
School of Medical Sciences 
..... l;l~alth campus 
T/TANGAN PEB®JtStSisains M~laysla 
J/K PENYELID~Kubang Kenan, Ketantan 
PUSAT PENGAJIAN 
5 
·~ 
TABLE OF CONTENTS 
1 
2. 
3.0 
ABSTRACT 
INTRODUCTION 
METERIALS AND METHODS 
2.1 Normal Cells and AML Cells 
2.1.1 Establishment and characterization 
of AML cells lines 
2.2 TEST PROCEDURES 
2.2.1 Isolation and Separation of PSP 
2.2.2 CM-Sephadex C-25 Column Chromatography 
2.2.3 Western Blotting 
2.2.4 Immunohistochemistry 
2.2.5 In-Vitro Study on Cell Proliferation 
2.2.5.1 Colony Forming Assay 
2.2.5.2 Suspension Culture Assay 
RESULTS 
3.1 Isolation and Purification of PSP 
3.2 Immunohistochemistry 
3.3 In-Vitro Study on Cell Proliferation 
3.3.1 Effect of PSP on AML Cell Growth 
Page 
1 
2 
5 
5 
5 
8 
8 
9 
9 
10 
10 
10 
11 
11 
11 
12 
14 
14 
... 
3.3.1.1. 
DISCUSSION 
Colony-forming assay and Suspension 
culture assay 
ACKNOWLEDGEMENTS 
REFERENCES 
APPENDICES 
Appendix A: 
Appendix B: 
LIST OF TABLE 
Tablet. 
LIST OF FIGURES 
Borang maklumat dan keizinan pesakit 
Borang maklumat dan keizinan pesakit; 
halaman tandatangan 
Characteristics of the patients from whom the 
AML cells Originated 
Figure 3.1 SDS-PAGE of the purified PSP proteins 
Figure 3.1.1 Immunoblot of PSP-Iike protein from normal 
human monocytes 
Figure 3.2 Immunohistochemical staining of monocytes and 
blast cells of AML for PSP-Iike protein 
Page 
14 
14 
16 
16 
19 
19 
6 
12 
12 
13 
ii 
q 
, 
A STUDY ON THE PRESENCE, ROLE AND SIGNIFICANCE OF 
PERCHLORIC-ACID SOLUBLE PROTEIN (PSP) IN BLAST CELLS OF ACUTE 
LEUKEMIC PATIENTS. 
Abstract 
The purpose of this study was to detect the presence of perchloric-acid-soluble protein 
(PSP) in blast cells of acute leukemic patients and to conduct in-vitro study on the 
possibility of blast cells be proliferated into matured cells when treated with PSP. 
Samples from acute myeloblastic leukemic (AML) patients and monocytes from healthy 
donor were used as a test subject. The small amount of perchloric-acid-soluble 14.5 kDa 
protein (PSP) was isolated from monocytes of healthy donor by a combination of 
trichloroacetic acid extraction, preparative electrophoresis and CM-Sephadex 
chromatography. However, this protein was not found in blast cells of AML patients. The 
14.5 kDa protein showed a strong cross-reactivity when tested with PSP antibody 
suggesting a close similarity to p 14.5 PSP found in mononuclear phagocytes of human. 
However in our in-vitro study on the proliferation of blast cells of AML samples after 
treated with PSP showed some reaction, but no significant results. Thus, we believed that 
the amount of PSP used in this study was too small which was not enough to play a 
significant role in cell development and maturity. 
Keywords: Acute leukemia; Perchloric-acid-soluble protein; blast cells; monocytes 
.. 
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1. INTRODUCTION. 
Perchloric-acid soluble protein (PSP) was first isolated and characterized by Oka et al., 
(1995) from the rat liver (L-PSPl) followed by Ceciliani et al., (1996) from the goat liver, 
Samuel eta/. (1997) from the mouse liver, Asagi et al., (1998) from the rat kidney (K-
PSP1) and recently by Nordin et al., (2000) from the avian tissues and designated as C-
PSP. The PSP isolated from the avian tissues was mainly expressed in the liver, kidney 
and also significantly expressed in intestine, gizzard, glandular stomach, heart, brain and 
spleen (Nordin et al., 2000). This protein exhibited a very high degree of identity with a 
group of protein belonging to the so-called Y ABJ and Y5GF isolated from Bacillus 
subti/is and E. coli, Ceciliani et al., (1996) . 
The PSP is a homodimer consisting of two identical subunits with a molecular mass of 14 
kDa. The eDNA of L-PSP1 contained a 411 bp, encoding a 137 amino-acid protein with 
a molecular mass of 14149 kDa. The deduced amino acid sequence of L-PSP1 was 
completely identical with that of K-PSP. L-and K-PSP also inhibited a cell-free protein 
synthesis in lysate of rabbit reticulocytes in a different manner from RNAse A (Oka et 
al., 1995; Asagi et al., 1998). These inhibition processes was mainly due to an 
endoribonucleolytic activity of L-PSP by direct effect on mRNA template and induced 
disaggregation of the reticulocyte polysomes into 80s ribosomes, even in the presence of 
cycloheximide (Morishita et al., 1999; Nordin et el., 2000). 
In 1996, Schmiedeknecht et al., discovered the presence of the translation inhibition 
protein (14.5 kDa) designated as p14.5 from the mononuclear phagocytes of human. The 
2 
• 
protein was found to show a remarkable similarity with PSP protein as described by Oka 
et al., (1995). This protein was also present in liver, kidney and vessel wall section when 
tested by immunohistochemical technique. The expression of the mRNA of the 
translational inhibitor p14.5 (human homologue of L-PSPl) was significantly up-
regulated with the induction of differentiation to macrophages (Schmiedelmecht et al., 
1996). A similar phenomenon was observed in the synthesis of K-PSPl from rat kidney 
which increases from the 17th day to the 4th postnatal week, and then enters a steady-state 
level (Asagi et al., 1998). In contrast, the expression ofK-PSPl in renal tumor cells was 
down-regulated (Asagi et al., 1998). Thus the PSP and PSP-like proteins appear to be 
expressed in a growth and differentiation-dependent manner. 
Another PSP-like protein which belongs to the same family lmown as UK101 and UK 
114 has been shown to be involved in immune control of tumor growth (Bartorelli A et 
al., 1996). Its role in tumor cell proliferation, however, is still uncertain. Complement-
mediated cytotoxic activity has been demonstrated in the sera of UKl 01 and UK114-
treated animals (Bartorelli A et al., 1996), and both cytolysis and tumor inhibition have 
been observed in the sera of cancer patients (Bussolati et al., 1997). The therapeutic 
effect of UK101 and UK114 in experimental mammalian tumors has been studied 
(Bartorelli A et al., 1994; Racca et al., 1997), whereas their role in the prevention of 
carcinogenesis has not been investigated. Later works by Ghezzo et al., (1998), has 
shown that the UK101 inhibits carcinogenesis of DMBA-induced Syrian hamster cheek-
pouch squamous cell carcinoma. 
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Similarly this PSP protein's present in tumor cells could have some mediative effect on 
the cells proliferation and its expression. It is well documented that leukemia is a 
purposeless, malignant, neoplastic proliferation of abnormal leucocytes in heamatopoietic 
tissues. Based on the degree of differentiation of the leukemic cell line, leukemias are 
divided into acute and chronic forms. Undifferentiated heamatopoietic cells are 
responsible for acute leukemias. Whereas differentiated cells are associated with chronic 
leukemias. AML is characterized by progressive accumulation of relatively immature, 
poorly functioning myeloid blasts in the bone marrow (BM) and peripheral blood (PB). It 
eventually leads to inhibition of the production and proliferation of cells within the 
normal hematopoietic compartments (Broxmeyer et al., 1985). AML is diagnosed 
morphologically, using the criteria proposed by the French-American-British (FAB) Co-
operative group (Bennet et al., 1976). Based on the previous studies that the PSP play an 
important role in protein inhibition and regulation of cell proliferation, therefore we 
undertake this study with the following objectives: 
1. To detect the presence of PSP in blast cells of acute leukemias patients 
2. To conduct In-vitro study on the possibility of blast cells be proliferated into matured 
cells when treated with PSP. 
3. The outcome of this study will be useful to embark further research on the role and 
significance of PSP in blast cells of acute leukemias patients or perhaps its future 
treatment. 
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2. METERILAS AND METHODS 
2.1 Normal cells and AML cells 
Ten healthy donors of age between 20 to 45 years old and five patients of confirmed 
cases of AML were used in this study. The experimental protocols were explained to 
them before they were asked to sign a consent form (Appendix A). Fresh blood samples 
from healthy donor were collected into EDTA container to make up 1 mM concentration 
and store at 4 OC before used. Blood samples from PB and /or BM was drawn at the same 
time as those for clinical tests before chemotheraphy. The diagnosis of AML was base on 
May-Griinwald-Giemsa (MGG), Sudan B black, and esterase staining of bone marrow 
and blood smear according to FAB classification criteria. The study was carried out in 
according to the protocol approved by the research and Ethics Committee of the 
Universiti Sains Malaysia. 
2.1.1 Establishment and characterization of AML cells lines 
Mononuclear cells (including blast cells) were separated by Opty-Prep density-gradient 
medium technique as described by Graziani-Bowering et al., 1997). The cells then were 
cryopreserved at -70°C in the presence of 50% heat-inactivated fetal calf serum (FCS) 
(Gibco, Grand Island, NY, USA), 10% dimethyl sulfoxide (Aldrich-Chemie, Steinhein, 
Germany) and a-minimal essential medium (a-MEM, Gibco). For the cultures, the cells 
were quickly thawed, washed twice with a-MEM and cultured at a high cell density of 1-
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U/ml of interleukin-3 and IL-6, 100 U/ml of granulocytes-macrophage colony-
stimulating factor and 40 ng/ml of mast cell growth factor. After culturing for 6 to 12 
weeks in the above mentioned culture media, the cells were allowed to proliferate in 10% 
FCS and a-MEM for the next three months. Thereafter the cells were frozen at -70°C. For 
the experiments the cells were thawed and continuously grown in the presence of 10% 
FCS and a-MEM in a humid atmosphere at 37oC with 5% C02 at a cell density 3-
5x 105 /ml. Fresh medium was generally changed every 3-4 days, and every other day for 
experiments. 
Table 2.1.1. Characteristics of the patients from whom the AML cell lines originated. 
········································································································ 
AML-1 12/M BP Diagnosis 
AML-2 9/F PB Diagnosis 
AML-3 10/M PB Diagnosis 
AML-4 12/M PB Diagnosis 
AML-5 8/F PB Diagnosis 
. ~ :F: ·i~~~l~;· M~ ~~i~~ .b :Pa: ·~~ri~h~;~i bi~~d: ................................................ . 
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PART 1. 
1. Preparation of cells. Isolation of monocytes and blast cells 
by OptiPret Method 
l 
Centrifuged 
l 
Cells were homogenize1 in 50 mM Tris/HCL pH 7.4 
Dialyzed 
2. Separation and purification of proteins 
PART 2. 
Separation and purification ofPSP by CM-Sephadex 
C-25 column chromatography 
j 
Purified PSP were analyzed on SDS-PAGE electrophoresis, blotted onto 
nitrocellulose membranes and immunoblotted with antisera 
against rat PSP 
3. In-vitro study on the proliferation of blasts. 
Purified blast cells were cultured as described by Buick et al., (1977) 
With or without PSP rd incubate at 37"C in 5% C02 
The cells were blocked, sectioned and stained with immunohistochemical procedures. 
! 
Data and results were analyzed. 
Figure2.1. Experimental design of the study 
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2.2 TEST PROCEDURES 
2.2.1. Isolation and separation of PSP from normal monocytes and blats cells of 
AML by OptiPrep method. 
Human monocytes from healthy donors and blast cells from AML patients were isolated 
by the OptiPrep density-gradient medium technique as described by Graziani-Bowering 
et al., 1997. 1 0 ml of fresh blood were collected from healthy donor and from patient into 
EDTA container to make up 1mM concentration. The samples were then brought 
together with the reagents and equipments to 4°C before use. The OptiPret reagent was 
gently shaken before removing for aliquot. 4.24 ml of 40% (w/v) iodixanol working 
solution (WS) was added into 10 ml of blood sample and mixed well. In a 15 ml 
centrifuge tube, 5 ml of density barrier solution (1.072 g/ml) was layered over 5 ml of the 
blood and then layered with approx. 0.5 ml of solution B (RPMI containing 10% fetal 
cuff serum). Centrifuge at 700g in a swinging-bucket rotor for 30 min at 4°C. The cells 
that float on top was collected and diluted with 2 vol. of solution B and harvested by 
centrifugation. The cells then were homogenized in 50 mM Tris/HCL pH 7 .4, 250 mM 
sucrose, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride (PhMeS2F), 1 mM 
benzamidine, 1 J.lM leupeptin, 1 J.lM pepstatin A at 4°C using a loose-fitting moto-driven 
glass/Teflon homogenizer. After centrifugation at 10 000 X g for 30 min, the post-
mitochondrial supernatant (PMS) was obtained and treated with 60% perchloric acid 
making a 5% solution of PMS and then again centrifuged at 10 00 X g for 15 min. The 
supernatant was made up to 25% with trichloroacetic acid, and the precipitate collected 
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by centrifugation at a similar speed as the later procedure. The precipitate was washed 
with cold acetone and dried under vacuum. The dried material was then dialyzed against 
distilled water for 4 h and then dialyzed extensively against 0.1 M sodium phosphate 
buffer (pH 7.5) overnight. 
2.2.2 CM-Sephadex C-25 column chromatography 
After clarification by a 10 min centrifugation at 10 000 X g, the proteins in the dialysate 
were fractionated with saturated ammonium sulfate. The precipitate formed between 0 
and 40% saturation was collected by centrifugation at 1 0 000 X g for 10 min. The 
precipitate was then suspended in 0.1 M sodium phosphate buffer (pH 7 .5) and dialyzed 
against the same buffer. The dialyzed product was applied through a 2 X 30-cm column 
of CM-Sephadex C-25. Absorbance readings for protein were taken at 280 nm using 
Ultraspec 3000 spectrophotometer (Pharmacia Biotech) and the flow-through fractions 
were collected and electrophoresed by SDS-PAGE. Finally, protein fractions that cross-
reacted with PSP antibody were pooled and again subjected to electrophoresis. The 
corresponding protein fractions obtained were used as the purified protein in the 
subsequent study. 
2.2.3. Western blotting 
We analyzed the pure proteins in homogenate from normal human monocytes and from 
blast cells by SDS-PAGE using polyacrylamide gels (15%) according to the method 
described by Laemmli (1970). After electrophoresis, the proteins on the gels were blotted 
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onto nitrocellulose membranes (Schleicher and Schuell, Germany) and immunoblotted 
with antisera against rat PSP (Oka et al., 1995). 
2.2.4. Immunohistochemistry 
The cells were prepared for immunohistochemistry as described earlier (Soini et al., 
1992) by fixing in 10% neutral formalin for 2-3 days at room temperatures, after which 
the cells were pelleted by centrifugation. The cell pellet was suspended in melted 2% 
agarose, and the agarose block was further embedded in paraffin. About four J.tm-thick ( 4 
J.lm) sections were placed on slides and fixed with 70°C alcohol for 30 min. The slides 
then were blocked with PBS containing 20% normal goat serum and 1% BSA for 1 h and 
incubated for 1 h with polyclonal antibodies against PSP in PBS containing 0.1% BSA in 
a moist chamber. The slides were washed extensively with PBS and then incubated for 1 
h with 8 J.tg/ml horseradish peroxidase-conjugated goat anti-rabbit lgG (Oka). After 
washing with PBS, the slides were stained by the addition of 0.05% diaminobentizine and 
0.1% H20 2• After washing with PBS, the smears were counterstained with methyl green 
for 20 min, dehydrated and mount. Negative controls were prepared by using non-
immunized rabbit lgG as a primary antibody. 
2.2.5. In-vitro study on the proliferation of blast cells. 
2.2.5.1. Colony forming assay 
A modified semi-solid methylcellulose (me) method described by Buick and co-workers 
(Buick et al., 1977) was used to investigate the effect of PSP on the formation of 
clonogenic blast cell colonies. The cells were plated in 96-microwell plates in 0.1 ml of 
10 
basic growth medium [1 0% heat-inactivated FCS in a-MEM] and 0.9% me (Aldrich-
Chemie, Steinheim, Germany) with or without of PSP and incubated in a humidified 
atmosphere at 37°C with 5% C02 at a cell density of 3 x 103 cell/well. All the cultures 
were performed in triplicate. Colony formation was observed and classified using an 
inverted microscope. Colonies from three weBs/sample containing more than 20 ceiis 
were counted and the mean colony number was calculated. 
2.2.5.2. Suspension culture assay 
In the suspension culture, 1 x 106 cells were incubated in the presence or absence of PSP 
in 1 ml of basic growth medium in 24 multi-well plates (Becton Dickinson & Company, 
Lincoln Park, New Jersey, USA) as described previously by Nara & McCulloch, 1985. 
The cell number and viability were determined by vital dye exclusion (0.4% trypan blue, 
Sigma Chemical Co.Ltd., Irvin, UK) using standard hemocytometer. 
3.RESULTS 
3.1. Isolation and purification of PSP from normal human monocytes and blast cells 
ofAML. 
In this study, we described the isolation and purification of PSP-like protein found in the 
healthy donor monocytes for further investigation. However, this protein was not found 
in any blast cells of AML samples (Fig. 3.1 ). The protein obtained by extraction with 5% 
perchloric acid and 25% trichloroacetic acid from the supernatant was almost pure at this 
step. The PSP-like protein appeared in the flow through fractions of CM-Sephadex 
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chromatography and was shown to be homogenous by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and contained single protein with a 
molecular mass of 14.5 kDa (Fig.3.1). The immunoblotting result showed a strong cross-
reaction with rat PSP antibody suggesting that the purified protein is similar to a 
perchloric-acid-soluble protein purified 
1 2 3 
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Figure3.1. SDS-PAGE of the purified PSP protein. 
3: Molecular weight marker, 
2. PMS of normal human monocytes. 
1: PMS of blast cells of AML. 
3.2. Immunohistochemistry 
from rat liver (Fig.3.1.1). 
PSP Control 
Fig. 3.1.1. Immunoblot analysis of PSP-Iike 
protein from normal human monocytes. The 
Were electrophoresed in 15% SDS-PAGE 
And immunoblot was carried out as 
Under section 2.2.5. 
To further support the data related to the detection of PSP in monocytes and to prove that 
PSP was not present in blast cells of AML, immunohistochemistry was performed. In this 
preparations we showed that some immunopositive deposits were seen in smears 
containing monocytes obtained from the healthy donor but, no immunoreaction were 
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observed in smears containing blast cells from AML samples (Fig.3.2) . No reaction 
products were found in any control smears prepared using non-immunized rabbit IgG as 
the primary antibody (Fig.3.2). 
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Figure. 3.2. Immunohistochemical staining of monocytes and blast cells of AML for 
PSP-like protein. Left panels (b,d) show negative control, and right panels (a,c) are 
shown to be imrnunostained with anti C-PSP rabbit IgG. Immunoreactive product are 
shown in the monocytes section (a) but not blast cells of AML (c). 
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3.3. In-vitro study on proliferation of blast cells 
3.3.1. Effect of PSP on AML cell growth 
3.3.1.1. Colony-forming assay and Suspension culture assay 
Due to a small amount of PSP-like protein were used in this study, in-vitro study of blast 
cells proliferation using colony-performing assay and suspension culture assay was not 
significant. 
4. DISCUSSION 
In the present study, a small amount of PSP-like protein was isolated in the monocytes of 
the normal healthy donor (Fig.3.1). However, this protein was not found in blats cells of 
AML patients (Fig. 3.1). The molecular mass of the PSP-like protein was found to be 
14.5 kDa as assessed by SDS-PAGE (Fig.3.1). The eDNA of a 14.5 kDa protein showed 
a remarkable similarity to the p 14.5 PSP found in mononuclear phagocytes (MNP) of 
human as described by Schmiedeknecht et.al., (1996). Immunohistochemical 
observations also revealed that the PSP-like protein was cross-reacted with PSP anti sera. 
Study by Schmiedeknecht et.al. (1996) shown that circulating monocytes have only weak 
expression of PSP, while the higher differentiated alveolar macropages and the lipid-
laden macrophages within the atherosclerosis plague have more intensive 
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immunolabeling of this protein suggesting, that expression and appearance of PSP-like 
protein are cell-specific processes. 
In our study, although many healthy donor samples (10 donors) has been analyzed and 
tested several times however, the amount ofPSP-like protein isolated was too little. This 
is probably due to the separation technique we used was not appropriate or could be the 
samples used was not enough. Because of that the In-vitro study on possibility of blast 
cells of AML proliferation when treated with PSP using colony-forming assay and in 
suspension culture assay was shown no significant results. 
Based on our observation and supported by the previous studies ( Schmiedeknecht et.al., 
1996} shows that PSP play an important role in protein inhibition and regulation of cell 
proliferation, therefore we believe this protein possibly could play a significant role in 
helping blast cell of AML be proliferated into matured cells. To embark further research 
on the role of this PSP-like protein on blast cell of AML in future we suggest, the 
Ieukapheresis technique may be used to isolate monocytes as described by 
Schmiedeknecht et.al., (1996) or perhaps commercially prepared PSP may be useful. 
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Appendix A 
BORANG MAKLUMAT DAN KEIZINAN PESAKIT 
Kajian Pengesanan, Peranan dan keberkesanan 'Perchloric-Acid Soluble Protein' dalam 
sel blast dari pesakit leukemia akut. 
'A Study on the Presence, Role and Significance ofPechloric-Acid Soluble Protein (PSP) 
in blast cells of Acute Leukemic Patients'. 
Pengenalan 
Andalpenjaga dipelawa menyertai satu kajian penyelidikan secara sukarela yang 
melibatkan pengambilan darah anda/anak jagaan anda sebanyak 10 mi. Darah anda/anak 
jagaan anda akan diproses didalam makmal dan sejenis darah putih terpilih akan diuji 
untuk mengesan keujudan/kehadiran sejenis protein dikenali sebagai 'Perchloric-Acid 
Soluble Protein(PSP). Sekiranya protein ini tidak ujud didalan darah putih terpilih itu, 
darah anda/anak jagaan anda akan diuji seterusnya dengan menyuntik/dicampur dengan 
PSP yang diproses dari sel manusia normal serta dibiak didalam incubator pada suhu 
37°C + C02 selama beberapa hari bagi melihat perkembangan seterusnya. Sebelum 
anda/anak jagaan anda menyertai kajian ini anda/penjaga akan diberitahu secara lisan 
akan tatacara, manfaat dan resiko kajian ini. Anda/penjaga juga akan diberikan senaskah 
boring maklumat dan keizinan pesakit ini untuk simpanan sebagai rekod anda. 
Tujuan Kajian 
Peringkat pertama kajian adalah bertujuan untuk menentukan kehadiran/keujudan PSP 
didalam sel terpilih darah putih. Sekiranya PSP tidak wujud, peringkat kedua kajian 
adalah bertujuan untuk mengetahui samaada sel terpilih darah putih yang dicampur 
dengan beberapa kepekatan PSP boleh berkembang menjadi normal atau tidak?. 
Sekiranya penyelidikan ini berhasil, beberapa kajian seterusnya perlu dijalankan dan 
kemungkinan masalah perkembangan sel abnormal dari pesakit akut leukemia dapat 
diatasi. 
Kelayakan Penyertaan. 
Penyelidik yang bertanggungjawab dalam kajian ini akan berbincang akan kelayakan 
andalanak jagaan untuk menyertai kajian ini. Adalah dimaklumkan bahawa sekiranya 
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anda/anak jagaan mengidap penyakit leukemia myeloblastic akut (Acute myeloblastic 
leukemia,AML) andalah layak menyertainya. 
Beberapa keperluan untuk menyertai kajian ini. 
+ Anda/anak jagaan telah disahkan mengidap penyakit leukemia myelobalstik akut 
(AML). 
+ Anda/anak jagaan belum diberi sebarang rawatan kemoterapi atau lain-lain rawatan 
berkaitan pemyalit diatas. 
Prosedur Kajian 
Apabila anda/anak jagaan disahkan mengidap penyakit AML, sebanyak 10 ml darah 
anda/anak jagaan akan diambil oleh doctor/penyelidik yang bertanggungjawab. Darah 
anda!anak jagaan akan segera dihantar kemakmal untuk diproses bagi menjalankan kajian 
diatas. 
Resiko 
Sekiranya anda/anak jagaan menyertai kajian ini, mungkin anda/anak jagaan akan 
mengalami beberapa resiko, terutamanya semasa prosedur pengambilan darah. 
Kerahsiaan 
Segala maklumat mengenai laporan perubatan dan Iaporan makmal akan dirahsiakan oleh 
penyelidik terlibat dan tidak didedahkan kepada pihak umum melainkan jika ia 
dikehendaki undang-undang. 
Tandatangan 
Untuk dimasukan kedalam kajian ini, anda/ penjaga yang sah mesti menandatangani serta 
menarikhkan halaman tandatangan (lihat appendix B). 
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Appendix B 
Borang Maklumat dan Keizinan Pesakit 
Halaman Tandatangan 
Untuk menyertai kajian ini, anda/penjaga yang sah mesti menandatangan mukasurat ini. 
Dengan mendatangai mukasurat ini, saya mengesahkan yang berikut: 
+ Saya telah diberitahu dengan lisan dan telah membaca semua maklumat dalam 
boring maklumat dan keizinan pesakit ini, dan saya telah pun diberi masa yang 
mengcukupi untuk mempertimbangkan maklumat tersebut. 
+ Saya secara sukarela bersetuju menyertai kajian penyelidikan ini, mematuhi 
segala prosedur kajian dan memberi maklumat yang diperlukan oleh penyelidik 
atau m,ana-mana pihak yang terlibat. 
+ Saya telah pun menerima satu salinan boring maklumat dan keizinan pesakit 
untuk simpanan peribadi saya/penjaga . 
. . .. ........ .. . . . ... . . ... . .. .. ...... .. . . . .. . . . . .. . 
Nama Pesakit(Ditera atau ditaip) 
No.Kad Pengenalan Pesakit(Baru) 
Tandatangan Pesakit/Penjaga 
-----------------------------------------
Nama Individu yang mengendalikan 
Perbincangan keizinan(Ditera atau ditaip) 
--------------------------------------------
Tandatangan Individu Pengendali Perbincangan 
Keizinan. 
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No. Pesakit 
No.K/P. (Lama) 
Tarikh (ddMMyy) 
------------------------------
Tarikh ( ddmmyy) 
Jumlah Geran: 
Peruntukan 2002 
(Tahun 1) 
Peruntukan 2003 
(Tahun 2) 
Peruntukan 2004 
(Tahun 3) 
Kwg Akaun P1J Projek 
304 11000 PPSP 6131243 
304 14000 PPSP 6131243 
304 15000 PPSP 6131243 
304 21000 PPSP 6131243 
304 22000 PPSP 6131243 
304 23000 PPSP 6131243 
304 2·t000 PPSP 6131243 
304 25000 PPSP 6131243 
304 26000 PPSP 6131243 
304 27000 PPSP 6131243 
304 28000 PPSP 6131243 
304 29000 PPSP 6131243 
304 32000 PPSP 6131243 
304 35000 PPSP 6131243 
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I A STUDY ON THE PRESENCE, ROLE AND SIGNIFICANCE OF 
PERCHLORIC-ACID SOLUBLE PROTEIN (PSP) IN BLAST CELLS OF ACUTE 
LEUKEMIC PATIENTS. 
Abstract 
The purpose of this study was to detect the presence of perchloric-acid-soluble protein 
(PSP) in blast cells of acute leukemic patients and to conduct in-vitro study on the 
possibility of blast cells be proliferated into matured cells when treated with PSP. 
Samples from acute myeloblastic leukemic (AML) patients and monocytes from healthy 
donor were used as a test subject. The small amount ofperchloric-acid-soluble 14.5 kDa 
protein (PSP) was isolated from monocytes of healthy donor by a combination of 
trichloroacetic acid extraction, preparative electrophoresis and CM-Sephadex 
chromatography. However, this protein was not found in blast cells of AML patients. The 
14.5 kDa protein showed a strong cross-reactivity when tested with PSP antibody 
suggesting a close similarity to p 14.5 PSP found in mononuclear phagocytes of human. 
However in our in-vitro study on the proliferation of blast cells of AML samples after 
treated with PSP showed some reaction, but no significant results. Thus, we believed that 
the amount of PSP used in this study was too small which was not enough to play a 
significant role in cell development and maturity. 
Keywords: Acute leukemia; Perchloric-acid-soluble protein; blast cells; monocytes 
1. INTRODUCTION. 
Perchloric-acid soluble protein (PSP) was first isolated and characterized by Oka et al., 
(1995) from the rat liver (L-PSP1) followed by Ceciliani et al., (1996) from the goat liver, 
Samuel et al. (1997) from the mouse liver, Asagi et al., (1998) from the rat kidney (K-
PSP1) and recently by Nordin et al., (2000) from the avian tissues and designated as C-
PSP. The PSP isolated from the avian tissues was mainly expressed in the liver, kidney 
and also significantly expressed in intestine, gizzard, glandular stomach, heart, brain and 
spleen ( Nordin et al., 2000). This protein exhibited a very high degree of identity with a 
group of protein belonging to the so-called Y ABJ and Y5GF isolated from Bacillus 
subtilis and E. coli, Ceciliani et al., (1996). 
The PSP is a homod~mer consisting of two identical subunits with a molecular mass of 14 
kDa. The eDNA of L-PSP1 contained a 411 bp, encoding a 137 amino-acid protein with 
a molecular mass of 14149 kDa. The deduced amino acid sequence of L-PSP1 was 
completely identical with that of K-PSP. L-and K-PSP also inhibited a cell-free protein 
synthesis in lysate of rabbit reticulocytes in a different manner from RNAse A (Oka et 
al., 1995; Asagi et al., 1998). These inhibition processes was mainly due to an 
endoribonucleolytic activity of L-PSP by direct effect on mRNA template and induced 
disaggregation of the reticulocyte polysomes into 80s ribosomes, even in the presence of 
cycloheximide (Morishita et al., 1999; Nordin et el., 2000). 
In 1996, Schmiedeknecht et al., discovered the presence of the translation inhibition 
protein (14.5 kDa) designated as p14.5 from the mononuclear phagocytes of human. The 
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protein was found to show a remarkable similarity with PSP protein as described by Oka 
et al., (1995). This protein was also present in liver, kidney and vessel wall section when 
tested by immunohistochemical technique. The expression of the mRNA of the 
translational inhibitor pl4.5 (human homologue of L-PSPl) was significantly up-
regulated with the induction of differentiation to macrophages (Schmiedeknecht et al., 
1996). A similar phenomenon was observed in the synthesis ofK-PSPl from rat kidney 
which increases from the 17th day to the 4th postnatal week, and then enters a steady-state 
level (Asagi et al., 1998). fu contrast, the expression ofK-PSPl in renal tumor cells was 
down-regulated (Asagi et al., 1998). Thus the PSP and PSP-like proteins appear to be 
expressed in a growth and differentiation-dependent manner. 
Another PSP-like protein which belongs to the same family known as UK.101 and UK 
114 has been shown to be involved in immune control of tumor growth (Bartorelli A et 
al., 1996). Its role in tumor cell proliferation, however, is still uncertain. Complement-
mediated cytotoxic activity has been demonstrated in the sera of UK101 and UK.114-
treated animals (Bartorelli A et al., 1996), and both cytolysis and tumor inhibition have 
been observed in the sera of cancer patients (Bussolati et al., 1997). The therapeutic 
effect of UK101 and UK114 in experimental mammalian tumors has been studied 
(Bartorelli A et al., 1994; Racca et al., 1997), whereas their role in the prevention of 
carcinogenesis has not been investigated. Later works by Ghezzo et al., (1998), has 
shown that the UK1 01 inhibits carcinogenesis of DMBA-induced Syrian hamster cheek-
pouch squamous cell carcinoma. 
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Similarly this PSP protein's present in tumor cells could have some mediative effect on 
the cells proliferation and its expression. It is well documented that leukemia is a 
purposeless, malignant, neoplastic proliferation of abnormalleucocytes in heamatopoietic 
tissues. Based on the degree of differentiation of the leukemic cell line, leukemias are 
divided into acute and chronic forms. Undifferentiated heamatopoietic cells are 
responsible for acute leukemias. Whereas differentiated cells are associated with chronic 
leukemias. AML is characterized by progressive accumulation of relatively immature, 
poorly functioning myeloid blasts in the bone marrow (BM) and peripheral blood (PB). It 
eventually leads to inhibition of the production and proliferation of cells within the 
normal hematopoietic compartments (Broxmeyer et al., 1985). AML is diagnosed 
morphologically, using the criteria proposed by the French-American-British (FAB) Co-
operative group (Bennet et al., 1976). Based on the previous studies that the PSP play an 
important role in protein inhibition and regulation of cell proliferation, therefore we 
undertake this study to investigate the presence of PSP in blast cells of acute leukemias 
patients and to conduct In-vitro study on the possibility of blast cells be proliferated into 
matured cells when treated with PSP. 
4 
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2. METERILAS AND METHODS 
2.1 Normal cells and AML cells 
Ten healthy donors of age between 20 to 45 years old and five patients of confirmed 
cases of AML were used in this study. The experimental protocols were explained to 
them before they were asked to sign a consent form (Appendix A). Fresh blood samples 
from healthy donor were collected into EDTA container to make up lmM concentration 
and store at 4 OC before used. Blood samples from PB and /or BM was drawn at the same 
time as those for clinical tests before chemotheraphy. The diagnosis of AML was base on 
May-Griinwald-Giemsa (MGG), Sudan B black, and esterase staining of bone marrow 
and blood smear according to F AB classification criteria. The study was carried out in 
according to the protocol approved by the research and Ethics Committee of the 
Universiti Sains Malaysia. 
2.1.1 Establishment and characterization of AML cells lines 
Mononuclear cells (including blast cells) were separated by Opty-Prep density-gradient 
medium technique as described by Graziani-Bowering et al., 1997). The cells then were 
cryopreserved at -70~C in the presence of 50% heat-inactivated fetal calf serum (FCS) 
(Gibco, Grand Island, NY, USA), 10% dimethyl sulfoxide (Aldrich-Chemie, Steinhein, 
Germany) and a-minimal essential medium (cx-MEM, Gibco). For the cultures, the cells 
were quickly thawed, washed twice with cx-MEM and cultured at a high cell density of 1-
2x 106/ ml in cx-MEM and 10% FCS in the presence of the following growth factors: 100 
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U/ml of interleukin-3 and IL-6, 100 U/ml of granulocytes-macrophage colony-
stimulating factor and 40 ng/ml of mast cell growth factor. After culturing for 6 to 12 
• 
weeks in the above mentioned culture media, the cells were allowed to proliferate in 10% 
FCS and a-MEM for the next three months. Thereafter the cells were frozen at -70°C. For 
the experiments the cells were thawed and continuously grown in the presence of 10% 
FCS and a-MEM in a humid atmosphere at 37oC with 5% C02 at a cell density 3-
5x 105 /ml. Fresh medium was generally changed every 3-4 days, and every other day for 
experiments. 
Table 2.1.1. Characteristics of the patients from whom the AML eel/lines originated . 
........................................................................................................ 
Cell lines Age/Sex a Blast cell sources b Phase of the disease 
········································································································ 
AML-1 12/M BP Diagnosis 
AML-2 9/F PB Diagnosis 
AML-3 10/M PB Diagnosis 
AML-4 12/M PB Diagnosis 
AML-5 8/F PB Diagnosis 
....................................................................................................... 
a F, female; M, male; b PB, peripheral blood. 
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2.2 TEST PROCEDURES 
2.2.1. Isolation and separation of PSP from normal monocytes and blats cells of 
AML by OptiPrep method. 
Human monocytes from healthy donors and blast cells from AML patients were isolated 
by the OptiPrep density-gradient medium technique as described by Graziani-Bowering 
et al., 1997. 10 ml of fresh blood were collected from healthy donor and from patient into 
EDTA container to make up 1mM concentration. The samples were then brought 
together with the reagents and equipments to 4°C before use. The OptiPret reagent was 
gently shaken before removing for aliquot. 4.24 ml of 40% (w/v) iodixanol working 
solution (WS) was added into 10 ml of blood sample and mixed well. In a 15 ml 
centrifuge tube, 5 ml of density barrier solution (1.072 g/ml) was layered over 5 ml of the 
blood and then layered with approx. 0.5 ml of solution B (RPMI containing 10% fetal 
cuff serum). Centrifuge at 700g in a swinging-bucket rotor for 30 min at 4°C. The cells 
that float on top was collected and diluted with 2 vol. of solution B and harvested by 
centrifugation. The cells then were homogenized in 50 mM Tris/HCL pH 7 .4, 250 mM 
sucrose, 1 mM EDT A, 1 mM phenylmethylsulfonyl fluoride (PhMeS2F), 1 mM 
benzamidine, 1 J.!M leupeptin, 1 J.!M pepstatin A at 4°C using a loose-fitting moto-driven 
glass/Teflon homogenizer. After centrifugation at 10 000 X g for 30 min, the post-
mitochondrial supernatant (PMS) was obtained and treated with 60% perchloric acid 
making a 5% solution of PMS and then again centrifuged at 10 00 X g for 15 min. The 
supernatant was made up to 25% with trichloroacetic acid, and the precipitate collected 
by centrifugation at a similar speed as the later procedure. The precipitate was washed 
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with cold acetone and dried under vacuum. The dried material was then dialyzed against 
distilled water for 4 h and then dialyzed extensively against 0.1 M sodium phosphate 
buffer (pH 7 .5) overnight. 
2.2.2 CM-Sephadex C-25 column chromatography 
After clarification by a 10 min centrifugation at 10 000 X g, the proteins in the dialysate 
were fractionated with saturated ammonium sulfate. The precipitate formed between 0 
and 40% saturation was collected by centrifugation at 10 000 X g for 1 0 min. The 
precipitate was then suspended in 0.1 M sodium phosphate buffer (pH 7 .5) and dialyzed 
against the same buffer. The dialyzed product was applied through a 2 X 30-cm column 
of CM-Sephadex C-25. Absorbance readings for protein were taken at 280 nm using 
Ultraspec 3000 spectrophotometer (Pharmacia Biotech) and the flow-through fractions 
were collected and electrophoresed by SDS-PAGE. Finally, protein fractions that cross-
reacted with PSP antibody were pooled and again subjected to electrophoresis. The 
corresponding protein fractions obtained were used as the purified protein in the 
subsequent study. 
2.2.3. Western blotting 
We analyzed the pure proteins in homogenate from normal human monocytes and from 
blast cells by SDS-PAGE using polyacrylamide gels (15%) according to the method 
described by Laemmli (1970). After electrophoresis, the proteins on the gels were blotted 
onto nitrocellulose membranes (Schleicher and Schnell, Germany) and immunoblotted 
with antisera against rat PSP (Oka et al., 1995). 
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2.2.4. Immunohistochemistry 
The cells were prepared for immunohistochemistry as described earlier (Soini et al., 
1992) by fixing in 10% neutral formalin for 2-3 days at room temperatures, after which 
the cells were pelleted by centrifugation. The cell pellet was suspended in melted 2% 
agarose, and the agarose block was further embedded in paraffin. About four J.lm-thick (4 
J.lm ) sections were placed on slides and fixed with 70°C alcohol for 30 min. The slides 
then were blocked with PBS containing 20% normal goat serum and 1% BSA for 1 h and 
incubated for 1 h with polyclonal antibodies against PSP in PBS containing 0.1% BSA in 
a moist chamber. The slides were washed extensively with PBS and then incubated for 1 
h with 8 J.lg/ml horseradish peroxidase-conjugated goat anti-rabbit lgG (Oka). After 
washing with PBS, the slides were stained by the addition of 0.05% diaminobentizine and 
0.1% H20 2• After washing with PBS, the smears were counterstained with methyl green 
for 20 min, dehydrated and mount. Negative controls were prepared by using non-
immunized rabbit IgG as a primary antibody. 
2.2.5. In-vitro study on the proliferation of blast cells. 
2.2.5.1. Colony forming assay 
A modified semi-solid methylcellulose (me) method described by Buick and co-workers 
(Buick et al., 1977) was used to investigate the effect of PSP on the formation of 
clonogenic blast cell colonies. The cells were plated in 96-microwell plates in 0.1 ml of 
basic growth medium [1 0% heat-inactivated FCS in a-MEM] and 0.9% me (Aldrich-
Chemie, Steinheim, Germany) with or without of PSP and incubated in a humidified 
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atmosphere at 3 7°C with 5% C02 at a cell density of 3 x 103 celVwell. All the cultures 
were performed in triplicate. Colony formation was observed and classified using an 
inverted microscope. Colonies from three wells/sample containing more than 20 cells 
were counted and the mean colony number was calculated. 
2.2.5.2. Suspension culture assay 
In the suspension culture, 1 x 106 cells were incubated in the presence or absence of PSP 
in 1 ml of basic growth medium in 24 multi-well plates (Becton Dickinson & Company, 
Lincoln Park, New Jersey, USA) as described previously by Nara & McCulloch,1985. 
The cell number and viability were determined by vital dye exclusion (0.4% trypan blue, 
Sigma Chemical Co.Ltd., Irvin, UK) using standard hemocytometer . 
3. RESULTS 
3.1. Isolation and purification of PSP from normal human monocytes and blast cells 
ofAML. 
In this study, we described the isolation and purification ofPSP-like protein found in the 
healthy donor monocytes for further investigation. However, this protein was not found 
in any blast cells of AML samples (Fig. 3.1). The protein obtained by extraction with 5o/o 
perchloric acid and 25% trichloroacetic acid from the supernatant was almost pure at this 
step. The PSP-like protein appeared in the flow through fractions of CM-Sephadex 
chromatography and was shown to be homogenous by sodium dodecyl sulfate-
polyacrylamide ·gel electrophoresis (SDS-PAGE) and contained single protein with a 
10 
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molecular mass of 14.5 kDa (Fig.3.1). The immunoblotting result showed a strong cross-
reaction with rat PSP antibody suggesting that the purified protein is similar to a 
perchloric-acid-soluble protein purified 
1 2 3 
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Figure3.1. SDS-P AGE of the pmified PSP protein. 
3: Molecular weight marker, 
2. PMS of n01mal human monocytes. 
I: PMS of blast cells of AML. 
3.2. Immunohistochemistry 
from rat liver (Fig.3.1.1). 
Fig. 3.1.1. Immunoblot analysis ofPSP-like 
protein from normal human monocytes. The 
Were electrophoresed in 15% SDS-PAGE 
And immunoblot was carried out as 
Under section 2.2.5. 
To further support the data related to the detection of PSP in monocytes and to prove that 
PSP was not present in blast cells of AML, immunohistochemistry was performed. In this 
preparations we showed that some inununopositive deposits were seen in smears 
containing monocytes obtained from the healthy donor but, no immunoreaction were 
observed in smears containing blast cells from AML samples (Fig.3.2). No reaction 
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products were found in any control smears prepared using non-immunized rabbit IgG as 
the primary antibody (Fig.3.2). 
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Figure. 3.2. Immunohistochemical staining of monocytes and blast cells of AML for 
PSP-like protein. Left panels (b,d) show negative control, and right panels (a,c) are 
shown to be immunostained with anti C-PSP rabbit IgG. Immunoreactive product are 
shown in the monocytes section (a) but not blast cells of AML (c). 
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3.3. In-vitro study on proliferation of blast cells 
3.3.1. Effect of PSP on AML cell growth 
3.3.1.1. Colony-forming assay and Suspension culture assay 
Due to a small amount ofPSP-like protein were used in this study, in-vitro study of blast 
cells proliferation using colony-performing assay and suspension culture assay was not 
significant. 
4. DISCUSSION 
In the present study, a small amount ofPSP-like protein was isolated in the monocytes of 
the normal healthy donor (Fig.3.1). However, this protein was not found in blats cells of 
AML patients (Fig. 3.1 ). The molecular mass of the PSP-like protein was found to be 
14.5 kDa as assessed by SDS-PAGE (Fig.3.1). The eDNA of a 14.5 kDa protein showed 
a remarkable similarity to the p 14.5 PSP found in mononuclear phagocytes (MNP) of 
human as described by Schmiedeknecht et.al., (1996). Immunohistochemical 
observations also revealed that the PSP-like protein was cross-reacted with PSP anti sera. 
Study by Schmiedeknecht et.al. (1996) shown that circulating monocytes have only weak 
expression of PSP, while the higher differentiated alveolar macropages and the lipid-
laden macrophages within the atherosclerosis plague have more intensive 
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immunolabeling of this protein suggesting, that expression and appearance of PSP-like 
protein are cell-specific processes . 
In our study, although many healthy donor samples (10 donors) has been analyzed and 
tested several times however, the amount ofPSP-like protein isolated was too little. This 
is probably due to the separation technique we used was not appropriate or could be the 
samples used was not enough. Because of that the In-vitro study on possibility of blast 
cells of AML proliferation when treated with PSP using colony-forming assay and in 
suspension culture assay was shown no significant results. 
Based on our observation and supported by the previous studies ( Schmiedeknecht et.al., 
1996) shows that PSP play an important role in protein inhibition and regulation of cell 
proliferation, therefore we believe this protein possibly could play a significant role in 
helping blast cell of AML be proliferated into matured cells. To embark further research 
on the role of this PSP-like protein on blast cell of AML in future we suggest, the 
leukapheresis technique may be used to isolate monocytes as described by 
Schmiedeknecht et.al., (1996) or perhaps commercially prepared PSP may be useful. 
14 
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